New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:09 EDTRGLS, BIIBRegulus Therapeutics and Biogen enter into new collaboration agreement
Regulus Therapeutics (RGLS) announced that it has entered into a new collaboration agreement with Biogen (BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis, or MS, under its Regulus microMarkers division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
News For RGLS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 22, 2014
12:21 EDTBIIBBiogen upgraded to Outperform from Neutral at RW Baird
Subscribe for More Information
12:09 EDTRGLS, BIIBOn The Fly: Midday Wrap
Subscribe for More Information
11:38 EDTBIIBBiogen retreats after Tecfidera sales miss, patient death reported
Subscribe for More Information
11:01 EDTBIIBBiogen trading lower on slower growth, PML case, says Deutsche Bank
Deutsche Bank attributes the pullback in shares of Biogen (BIIB) to slower sequential revenue growth and the one PML case with Tecfidera disclosed on today's earnings call. Deutsche believes investors are now favoring Celgene (CELG) over Biogen due to near term headline risks. The firm says it likes Celgene more as well due its pipeline, but keeps a Buy rating on Biogen.
10:46 EDTBIIBBiogen shares defended at Morgan Stanley
Subscribe for More Information
10:42 EDTBIIBBiogen shares defended at Deutsche Bank
Subscribe for More Information
09:46 EDTBIIBBiogen falls, levels to watch
The shares are down sharply following Q3 results and a guidance boost for FY14, At the current price of $294.96, shares are lower by 9.8%. Support is at the session low at $290.94. Resistance is at $299.71.
09:21 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
09:12 EDTBIIBBiogen down 6% after Q3 report, disclosure of patient death
Subscribe for More Information
07:57 EDTRGLSRegulus Therapeutics to host conference call
Conference call to discuss interim results from the ongoing clinical study of RG-101 for treatment of HCV will be held on October 22 at 8:30 am. Webcast Link
07:34 EDTRGLSRegulus Therapeutics' RG-101 for hepatitis C shows positive results
Subscribe for More Information
07:08 EDTBIIBBiogen reports Q3 TECFIDERA revenues $787M
Subscribe for More Information
07:03 EDTBIIBBiogen raises FY14 adjusted EPS view to $13.45-$13.55, consensus $13.10
Still sees revenue growth 38%-41% vs. 2013, consensus $9.69B. $&D expense is expected to be approximately 20% to 21% of total revenue.
07:02 EDTBIIBBiogen reports Q3 adjusted EPS $3.80, consensus $3.46
Reports Q3 revenue $2.51B, consensus $2.48B.
October 21, 2014
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
06:54 EDTBIIBBiogen October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
October 20, 2014
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
October 14, 2014
11:23 EDTBIIBBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
08:08 EDTRGLSRegulus Therapeutics to present new preclinical data on multiple programs
Regulus Therapeutics (RGLS) announced that it will present new preclinical data on multiple programs and an overview of its clinical portfolio at the 10th Annual Oligonucleotide Therapeutics Society meeting being held October 12-October 15 at the Hilton San Diego Resort and Spa. In a poster titled "Anti-Diabetic Activity of miR-103/107 Anti-miRs", Regulus scientists will present preclinical data further demonstrating the potential benefit of a microRNA therapeutic for the treatment of metabolic disorders. In a poster titled "Inhibition of miR-21 with RG-012 Improves Renal Function and Survival in Multiple Strains of Col4A3 Deficient Mice", Regulus scientists, in collaboration with its strategic alliance partner Sanofi (SNY), will present new preclinical data demonstrating that weekly subcutaneous delivery of RG-012 has shown to provide both glomerular and tubule protection in the kidneys of Col4A3 deficient mice in an Alport syndrome model.
October 13, 2014
07:12 EDTRGLSOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use